INTRODUCTION
The diagnosis of IBD has to be made after excluding the possibility of infection. Since Taiwan is an endemic area for tuberculosis (TB), it is always required to be differentiated the TB from CD as always. To this issue, the steering committee of Taiwan Society of IBD (TSIBD) has arranged a seminar accordingly on May 24th, 2014 and a report of it has been generated afterwards. From the different point of views by gastroenterologist, radiologist, pathologist and infectious disease specialist, we hope this report can help our follow 
GASTROENTEROLOGIST'S OPINION
In geographical regions where ITB and CD coexist, it is difficult to differentiate CD from ITB. The natural course of these two diseases is quite different. ITB is curable when appropriate treatment provided whereas CD is a progressive relapsing illness. Diagnostic approaches rely on clinical, endoscopic, radiological, and pathological findings. Detailed information regarding the symptoms, duration of disease, history of previous TB, extra-intestinal manifestations and chest x-ray findings should be obtained. The tuberculin skin test (TST) had a high false positive rate in a highly BCG vaccinated population as Taiwan. 2 The colonoscopic features which suggest a diagnosis of CD include anorectal lesions, longitudinal ulcers, aphthous ulcers, cobblestone appearance. Features suggestive of ITB include transverse ulcers, involvement of fewer than four segments, a patulous ileocecal valve and scars or pseudopolyps. 3 However, the limitations of these scoring systems including small sample size, the positive predictive value was 90% of cases by scoring system, no validation studies in other geographical population; and most of all, the scoring system would not be useful when there' s no colon involved.
RADIOLOGIST'S OPINION
CT is an essential diagnostic tool as it can be used for the disease localization, evaluating the intestinal and mesenteric extent of the inflammatory process and assessing the extraluminal manifestation. When using the cross sectional images, the bowel wall thickening is usually symmetric and concentric in CD. There will be transmural enhancement in most incidence (Fig. 1 ). Other features include−intestinal stenosis ( Fig. 2 ), fistula formation ( Fig. 3) , multiple levels or segmental involvement. It is easy to demonstrate the lessfrequently involved ileocecal region as well as the mural stratification (target sign). 4 Extramural disease may present as increased mensenteric vascular stranding (comb sign) (Fig. 4 ) and fibrofatty proliferation in the mesentery; the latter is usually pathognomonic for CD. In ITB, ileocecal region is also a frequent site of involvement. In one study of 130 patients of gastrointestinal TB, the disease located in upper gastrointestinal tract in 8.5%, small bowel in 33.8% (ileocecal region), large bowel in 22.3%, peritoneum in 30.7% and liver in 14.6% were reported. 5 Ileocecal region involved up to 86% of ITB patients was also noted. 6 Asymmetric thickening of the bowel wall and large necrotic lymph nodes (Fig. 5 ) in the mesentery should raise the suspicion of ITB. 
PATHOLOGIST'S OPINION
To distinguish CD disease from ITB, in addition to the clinical presentation, endoscopic findings, as well as radiological and pathological H&E staining sections, acid fast stain and/ or TB PCR should be also be studied. According to CD diagnostic criteria in Japan: (1) Granuloma is aggregated of histiocytes. The etiology of granuloma included infection and non-infectious reaction. Suppurative granuloma, foreign body granuloma, non-caseating granuloma and caseating granuloma should be differentiated. Histology usually does not allow us to discriminate TB from CD. Clinical differences such as perianal fistulae and types of extraintestinal disease definitely help for further differentiation. A high index of suspicion of TB is required if the patient were immunosuppressed, from high prevalence areas or had history of travel to high prevalence areas. Granulomas were frequently detected in ITB. 9 In a study compared the pathologic features between TB and CD, the result showed high frequency of confluent granulomata (50 vs. 0%), ≥10 granulomata/biopsy site (33 vs. 0%), caseous necrosis (22 vs. 0%) in TB patients. 10 Absence of focally enhanced colitis and no involvement of sigmoid colon were also independent predictors of ITB. 11 Higher positivity and reliable results were found in tissue culture, Ziehl-Neelsen stain, and PCR. Ziehl-Neelsen stain and TB PCR could be done by using tissue/DNA from paraffin embedded tissue block. Overall speaking, we should exclude the possibility of TB by any kinds of methods available in our hands. 
Diagnosis of LTBI
The only method to diagnose LTBI is host immune response. Symptomatology, mycobacteriology and radiology could only exclude active TB disease. The TST is a long-term used screening tool for LTBI. In this test, a mixture of proteins from M. tuberculosis were used as antigens. A false-positive result may therefore result from previous BCG vaccination or non-tuberculous mycobacteria infection. Two Interferongamma release assays (IGRAs) are newly developed for the diagnosis of LTBI. The QuantiFERON-TB (QFT) Gold uses ELISA to quantify interferon-gamma (IFN-g) released from sensitized lymphocytes in whole blood. The other test, the T-SPOT.TB, uses enzyme-linked immunospot to count the number of peripheral blood mononuclear cells that produce IFN-g. Both tests use M. tuberculosis -specific antigens, including ESAT-6, CFP-10, and TB7.7, and therefore unaffected by BCG vaccination.
Pooled estimates of sensitivity were lowest for the TST (70%), higher for QFT (76%), and highest for T-SPOT.TB (88%). Pooled specificity was 97.7% for QFT and 92.2% for T-SPOT. TB. Pooled specificity was 66% for TST. Further analysis showed the specificity of TST was 56% in BCG-vaccinated population and 98% in non-BCG vaccinated group. 
Risk of Developing Active TB
Risk factors of TB includes LTBI, advanced human immunodeficiency virus infection, anti-tumor necrosis factor (TNF) agents, old age, healed TB that was not treated, poorly controlled diabetes , tobacco exposure, chronic renal failure, silicosis, gastrectomy, and underweight. 
Treatment of ITB and LTBI
For ITB, therapeutic regimen is the same as pulmonary TB, consisting of Isoniazid (INH; 5 mg/kg/day), Rifampin (RMP; 10 mg/kg/day), Ethambutol (EMB; 15−20 mg/kg/day) and Pyrazinamide (PZA; 20−25 mg/kg/day) in the first 2 months (intensive phase), followed by INH and RMP (+EMB) for 4 months (continuation phase).
Four regimens are now recommended for the treatment of LTBI: (1) INH 300 mg (5 mg/kg) daily for 6−9 months; (2) RMP 600 mg (10 mg/kg) daily for 4 months; (3) INH 300 mg (5 mg/kg) plus RMP 600 mg (10 mg/kg) daily for 3 months; and (4) INH 900 mg (15 mg/kg) plus Rifapentine 900 mg (15 mg/kg) weekly for 12 doses. 13 For IBD patients under biological agents, symptoms and signs of active TB disease should be monitored monthly. Chest radiography and IGRA may be performed every 6 months. Consult TB specialist when necessary.
CONCLUSIONS
CD and ITB are difficult to differentiate from one another. Combination of clinical manifestations, endoscopic, radiologic and histological features helps us to distinguish these two diseases. TB is one of most communicable diseases in Taiwan. The diagnostic tools of LTBI include TST and IGRA. Screening for LTBI before and regular monitor active TB while using biological agents are highly recommended.
